10/17/2026
CAR T-cell therapy, initially developed to treat certain blood cancers, is showing potential as a treatment for people with severe lupus, an autoimmune disease in which the immune system mistakenly attacks healthy tissues and organs.
A 2025 systematic review published in *Naunyn-Schmiedeberg's Archives of Pharmacology* analyzed 10 studies involving 47 lupus patients who received CAR T-cell therapy after conventional treatments had failed. Researchers reported that 81% achieved remission or very low disease activity, and many were able to discontinue their lupus medications. Some patients maintained remission without medication for extended periods, with follow-up lasting up to 46 months.
Unlike conventional lupus treatments, which generally suppress immune activity, CAR T-cell therapy uses genetically modified immune cells to target and eliminate B cells involved in producing harmful antibodies. The review also reported improvements in lupus symptoms, reductions in disease-related antibodies, and better kid